Levels and adherens junction integrity. Hepatology 2009, 50, 1567576. 147. Lim, S.J.; Lee, S.H.; Joo, S.H.; Song, J.Y.; Choi, S.I. Cytoplasmic expression of HuR is associated to cyclooxygenase-2 expression in colon cancer. Cancer Res. Treat. 2009, 41, 872. 148. Liang, P.I.; Li, W.M.; Wang, Y.H.; Wu, T.F.; Wu, W.R.; Liao, A.C.; Shen, K.H.; Wei, Y.C.; Hsing, C.H.; Shiue, Y.L.; et al. HuR cytoplasmic expression is related to elevated cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer 2012, 12, 611. 149. Heinonen, M.; Hemmes, A.; Salmenkivi, K.; Abdelmohsen, K.; Vil , S.T.; Laakso, M.; Leidenius, M.; Salo, T.; Hautaniemi, S.; Gorospe, M.; et al. Function of RNA binding protein HuR in ductal carcinoma in situ on the breast. J. Pathol. 2011, 224, 52939. 150. Lauriola, L.; Granone, P.; Ramella, S.; Lanza, P.; Ranelletti, F.O. Expression in the RNA-binding protein HuR and its clinical significance in human stage I and II lung adenocarcinoma. Histol. Histopathol. 2012, 27, 61726. 151. Tran, H.; Maurer, F.; Nagamine, Y. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol. Cell Biol. 2003, 23, 7177188.Int. J. Mol. Sci. 2013,152. Dong, R.; Lu, J.G.; Wang, Q.; He, X.L.; Chu, Y.K.; Ma, Q.J. Stabilization of Snail by HuR inside the process of hydrogen peroxide induced cell migration. Biochem. Biophys. Res. Commun. 2007, 356, 31821. 153. Lee, Y.R.; Noh, E.M.; Oh, H.J.; Hur, H.; Kim, J.M.; Han, J.H.; Hwang, J.K.; Park, B.H.; Park, J.W.; Youn, H.J.; et al.Favezelimab Dihydroavenanthramide D inhibits human breast cancer cell invasion by way of suppression of MMP-9 expression.Rezvilutamide Biochem. Biophys. Res. Commun. 2011, 405, 55257. 154. Noh, E.M.; Lee, Y.R.; Hur, H.; Kim, J.S. Radix clematidis extract inhibits TPA-induced MMP-9 expression by suppressing NF-kappaB activation in MCF-7 human breast cancer cells. Mol. Med. Report. 2011, four, 87983. 155. Hsia, T.C.; Tu, C.Y.; Chen, Y.J.; Wei, Y.L.; Yu, M.C.; Hsu, S.C.; Tsai, S.L.; Chen, W.S.; Yeh, M.H.; Yen, C.J.; et al. Lapatinib-mediated COX-2 Expression Via EGFR/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells. Mol. Pharmacol. 2013, 83, 85769. 156. Filippova, N.; Yang, X.; Wang, Y.; Gillespie, G.Y.; Langford, C.; King, P.H.; Wheeler, C.; Nabors, L.B. The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol. Cancer Res. 2011, 9, 64859. 157. Urano, N.; Fujiwara, Y.; Doki, Y.; Kim, S.J.; Miyoshi, Y.; Noguchi, S.; Miyata, H.; Takiguchi, S.; Yasuda, T.; Yano, M.; et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.PMID:23381626 Int. J. Oncol. 2006, 28, 37581. 158. Lee, K.M.; Cao, D.; Itami, A.; Pour, P.M.; Hruban, R.H.; Maitra, A.; Ouellette, M.M. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology 2007, 51, 53946. 159. Seve, P.; Isaac, S.; Tredan, O.; Souquet, P.J.; Pacheco, Y.; Perol, M.; Lafanechere, L.; Penet, A.; Peiller, E.L.; Dumontet, C. Expression of class III -tubulin is predictive of patient outcome in individuals with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin. Cancer Res. 2005, 11, 5481486. 160. Raspaglio, G.; de Maria, I.; Filippetti, F.; Martinelli, E.; Zannoni, G.